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Antiulcer and antiproliferative properties of spent
brewer’s yeast peptide extracts for incorporation
into foods
Maria M. Amorim,a Joana O. Pereira,a Karin M. Monteiro,b,c Ana L. Ruiz,b
João E. Carvalho,b,d Hélder Pinheiroe and Manuela Pintado*a
The main objective was to study the antiulcer and antiproliferative potential of yeast peptide extract for
further incorporation into functional foods. Peptide concentrates were obtained by hydrolysis of spent
brewer’s yeast proteins followed by a filtration process. In order to prove the possible protection of gastric
mucosa, an animal model with ulcerative lesions caused by oral administration of absolute ethanol was
used. The peptide fraction <3 kDa was able to reduce gastric injuries to significant levels (p < 0.001) and
the effective dose (DE50) was 816 mg per kg bw. The cytoprotective effect appears to depend on a
prostaglandin-mediated mechanism and also on a nonspecific mechanism. The antiproliferative activity of
the extract in nine different human tumoral cell lines was tested. The results exhibited a promising anti-
proliferative activity against the cell line K-562 (leukemia). The results suggest that a new peptide extract
can be used to develop new value-added functional food products, although further studies are required.
1. Introduction
Currently, human population is concerned about avoiding
harmful foods and at the same time increasing dietary ingredi-
ents which stimulate well-being and contribute to improve the
quality of life. Aligned with this consumer trend, new foods
have been developed to promote health benefits via their
physiological activities in the body, providing a healthy state of
life and chronic disease control.1
Brewer’s yeast (Saccharomyces sp.) is an inexpensive nitro-
gen source, generally recognized as safe (GRAS) and has good
nutritional characteristics,2 since it is rich in complex B vita-
mins (B1, B2, B6, pantothenic acid, niacin, folic acid and
biotin), minerals, macro and trace elements, particularly
selenium and dietary fiber, mainly represented by cell wall
carbohydrates, namely mannans and glycans.3 Additionally, a
few bioactive properties have been reported for yeast hydro-
lysates such as anti-obesity effects in high fat rats.4 Mantovani
et al.5 have reported other biological activities specifically for
glucans from yeast extracts, namely, anti-cytotoxic, anti-muta-
genic and anti-tumorigenic effects.
However, until now the effect of brewer’s yeast or derived
extracts on gastric protection has never been studied. Chronic
diseases are considered one of the great problems of modern
population. They tend to be progressive, with considerable
impact on patient’s quality of life, and in many cases may lead
to the development of malignant neoplasms. Epidemiological
studies highlight the prevalence of gastric disease, attributed
to several factors, such as, dietary habits with a low intake of
micronutrients and high nitrate content; prevalence of Helico-
bacter pylori; and genetic variations.6 Peptic ulcers are one of
the most common lesions,7 characterized by the onset of acute
or chronic ulcerative lesions in the gastric mucosa exposing
the aggressive action of the acid-peptic juice.8 Evidence indi-
cates that peptic ulcerogenesis (gastric or duodenal) results
from an imbalance between protective substances, viz. mucus,
bicarbonate, prostaglandins, sulphydryl compounds such as
proteins and glutathione, and promoter factors such as H. pylori
infection and/or exposure to damaging chemical agents.9
Some studies have reported on the positive effects of
specific food ingredients, namely α-lactalbumin that showed a
positive effect on the protection of rat stomach mucosa against
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ulcerative lesions via stimulation of prostaglandins and mucus
production,10 as well as other whey proteins and collagen
extracts,11 among others. The development of new compounds
with anti-secretory activity and gastro protective effects may
represent a promising approach to the successful treatment of
peptic ulcer and gastric damage and may be complementary
with other therapeutic modalities.
Additionally, the increasing incidence of cancer in the
world is also a well-documented fact. According to the Inter-
national Agency for Research on Cancer (IARC), the world
impact of cancer has duplicated in 30 years.12 Some bioactive
compounds possess the ability to protect the body from malig-
nant cell proliferation caused by free radical-induced oxidative
stress.13 The research of new antioxidant sources has been
increasing and could play a crucial role in the elimination of
free radicals in the body. Regarding yeast extracts, the litera-
ture emphasizes that they contain several endogenous sub-
stances that may act as antioxidants.14 They possess enzymatic
components such as superoxide dismutase, catalase, or gluta-
thione (GSH) reductase as well as nonenzymatic compounds
like GSH, ubiquinone, sulfhydryl amino acid, or mineral
ions.15 Recently, some studies associated the use of yeast with
antiproliferative actions in some cancer cell lines namely,
breast cancer cells,16,17 prostate cancer cells and melanoma
cells,18 tongue and colon cancer cells.19
Thus, the present work aims to study the potential anti-ulcer
effect of different molecular weight fractions of brewer yeast
extract, obtained by hydrolysis with Cynara cardunculus pro-
teases, in animal models with ethanol-induced gastric ulcer. On
the other hand, the screening of the antiproliferative effect on
different types of cancer cell lines was also investigated. All the
studies were performed with the assumption that the extracts
can be considered ingredients that can be further used for poss-
ible applications as ingredients for the development of novel
functional food products or as supplements.
2. Materials and methods
2.1 Brewer’s yeast extract
Brewer’s yeast extract was obtained after autolysis of the spent
brewer yeast, kindly provided by Unicer (Porto, Portugal). After-
wards, the mixture was ultrafiltered with a 10 kDa cut-offmem-
brane and hydrolyzed with proteases from an aqueous extract
of Cynara cardunculus (Formulab, Maia, Portugal), according
to a process described by Amorim et al.20 Freeze dried frac-
tions used were retentate MW >3 kDa – BYPC, and a nano-
filtrate fraction with MW < 3 kDa – BYPP.
2.2 Anti-ulcer activity
2.2.1 Animals and feeding. Male Wistar rats (200–250 g)
acquired from the Experimental Animal Center (CEMIB) of
Campinas University, were used. During the maintenance
period, at least seven days prior to the study, all animals were
grouped and housed in polycarbonate cages, under a climate-
controlled environment (22 °C ± 3 °C and relative humidity
30–70%) and a 12 h light/dark cycle. The animals were sup-
plied ad libitum of conventional standard pelletized laboratory
diet (Nuvilab®, Curitiba, Brazil) and tap water. Animal welfare
guidelines were adopted (Guide for the Care and Use of Labo-
ratory Animals 1996). The protocols employed in the study
are in agreement with the Ethical Principles for Experimen-
tation of Animals adopted by the Brazilian Society of Science
in Laboratory Animals (SBCAL) and previously approved by the
Animal Ethics Committee on Animal Use CEUA/UNICAMP
(Protocol number 2407-1).
2.2.2 Ethanol-induced gastric ulcer. Ethanol-induced
gastric ulcer was carried out according to the method of Mori-
moto et al.21 For induction of gastric mucosa ulcerative
lesions, 6 rats were randomly assigned to each treatment. In
accordance with Robert,22 the groups were subjected to oro-
gastric intubation with a gavage cannula for the administration
of the following treatments: negative control consisted of 0.9%
sodium chloride solution, positive control with carbenoxolone
(Sigma-Aldrich) 200 mg per kg bw, and different single dose
levels 100, 300 and 1000 mg kg−1 of BYPC >3 kDa and BYPP
<3 kDa. One hour after the treatment, all rats received orally
1 mL 99.9% absolute ethanol as an ulcerogenic agent. After
1 h, the animals were euthanized by cervical dislocation and
their stomachs were opened along the line of the greater curva-
ture. After washing the stomachs with saline solution, the
ulcerative lesions were assessed.
2.2.3 Assessment of ulcerative lesions (ULI). The degree of
anti-ulcerative activity in the experimental groups was assessed
according to Gamberini et al.37 The presence of different types
of lesions, were counted and scored as presented in Table 1.
The ULI was calculated by the sum of all the pathological para-
meters observed and the percentage of inhibition of ulcerative
lesions was calculated by comparing the lesions in the experi-
mental treatment group of animals and negative control (0.9%
saline solution), using eqn (1):
½ðAverage control Average test sampleÞ=Average control  100
ð1Þ
In order to estimate the effective dose, ED50 of the sup-
plement was calculated by interpolation, after linear regression
of the experimental data.
Table 1 Ulcerative lesion index score (ULI)
Lesion type Point
Loss of normal morphology 1 point
Discoloration of mucosa 1 point
Mucosal edema 1 point
Hemorrhages 1 point
Petechial points
Until 9 petechial 2 points
>10 petechial 3 points
Ulcers up to 1 mm n × 2 pointsa
Ulcers >1 mm n × 3 pointsa
Perforated ulcers n × 4 pointsa
a n number of ulcers.
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2.2.4 Study of the involvement of different cytoprotection
mechanisms
2.2.4.1 Nitric oxide (NO). The participation of NO on gastric
protection was accomplished as follows: a 5 mg per kg bw
solution of N-ω-L-arginine methyl ester, L-NAME (Sigma-
Aldrich) was administered intraperitoneally to each group
(6 animals), as described by Konturek and Pawlik23 and each
group had 6 animals. After 30 min, the control group received
10 mL per kg bw saline solution orally, and the other group
received 812 mg per kg bw BYPP <3 kDa dissolved in a saline
solution. After 30 min, all rats were treated with 1 mL of abso-
lute ethanol administered orally. The following steps were per-
formed as previously described in ethanol-induced gastric
ulcer and the anti-ulcerative activity degree (% ULI) was calcu-
lated using eqn (1).
2.2.4.2 Sulphydryl compounds. The assessment of the involve-
ment of sulfhydryl groups in gastric protection was per-
formed using N-ethylmaleimide, NEM (Sigma-Aldrich) as a
blocking agent. All animals received a subcutaneous injection
of 10 mg per kg bw to each group (6 animals), as described by
Szabo et al.24 After 30 min, the control group received 10 mL
per kg bw of saline solution administered orally, and the other
group received 812 mg per kg bw BYPP <3 kDa dissolved in a
saline solution. After 30 min, all rats were treated orally with
1 mL of absolute ethanol. The following steps were performed
as previously described in ethanol-induced gastric ulcer and
the anti-ulcerative activity degree (% ULI) was calculated using
eqn (1).
2.2.4.3 Prostaglandins. The participation of endogenous PG
in gastric protection was carried out according to Szabo et al.24
as follows: a 30 mg per kg bw solution of indomethacin
(Sigma-Aldrich) was injected subcutaneously to each group
(6 animals). After 30 min, the animals were separated and one
group received 812 mg per kg bw BYPP <3 kDa dissolved in a
saline solution and the other group received 10 mL per kg bw
of saline solution orally. After another 30 min, the animals
were treated orally with 1 mL of absolute ethanol, and sacri-
ficed 1 h later. The following steps were performed as pre-
viously described in ethanol-induced gastric ulcer and the
anti-ulcerative activity degree (% ULI) was calculated using
eqn (1).
2.3 Antiproliferative activity
2.3.1 Cell lines. Nine human tumor cell lines, U251
(glioma, CNS), UACC-62 (melanoma), MCF-7 (human breast
adenocarcinoma), NCI-ADR/RES (breast expressing phenotype
multiple drug resistance), 786-0 (kidney), NCI-H460 (lung,
non-small cells), PC-3 (prostate), OVCAR-3 (ovarian), HT-29
(human colon adenocarcinoma) and Vero (kidney, non-cancer
cell line, African green monkey) were provided by the National
Cancer Institute (NCI-USA).
2.3.2 Antiproliferative assay. The in vitro antiproliferative
activities of BYPC >3 kDa and BYPP <3 kDa were assessed, as
described by von Staszewski et al.25 using stock cultures that
were grown in a medium containing RPMI 1640 (GIBCO BRL)
supplemented with 5% of fetal bovine serum (GIBCO) and
50 μg mL−1 of gentamicin (Sigma-Aldrich). The adherent cell
lines were detached from the culture flasks by adding a
0.025% trypsin solution (Nutricell Nutrientes Celulares, Cam-
pinas, SP, Brazil). The cells were transferred to 96-well micro-
plates (Nunc™) in a fixed volume of 100 μL per well and
exposed to various concentrations of BYPC >3 kDa and BYPP
<3 kDa (0.25–250 μg mL−1) in DMSO (0.1% v/v) at 37 °C and
5% CO2 for 48 h. Afterwards, cells were fixed with 50% tri-
chloroacetic acid and cell proliferation was determined by
spectrophotometric quantification (540 nm) of cellular protein
content, with the sulforhodamine B assay.26 Cell proliferation
was determined according to Euzébio et al.27 Concentration–
response curves for each cell line were determined by non-
linear regression analysis using Origin software, version 7.5
(OriginLab Corporation).
2.4 Statistical analysis
All results were subjected to analysis of variance (ANOVA) with
significance level p < 0.001 considered to be significant differ-
ences between the control and treated groups, followed by the
Duncan test.
3. Results and discussion
3.1 Antiulcer activity of brewer’s yeast extracts
An ethanol-induced ulcer model was employed for screening
the antiulcer activity of yeast extracts. Acute administration of
BYPP <3 kDa showed an anti-ulcerative effect with increasing
doses of 100, 300 and 1000 mg kg−1 on gastric ULI caused by
ethanol, and the highest concentration of BYPP <3 kDa –
1000 mg per kg bw – caused reduction of 63.4% of the ulcer
damage with statistical significant differences (p < 0.001).
Fig. 1 shows typical morphology of ethanol-induced gastric
ulcers, which occurred on the mucosa, parallel to the long axis
of the stomach – negative control (saline solution). In rats
treated with BYPP <3 kDa, the stomach appears almost normal
with no damage caused by the alcohol effect with an appear-
Fig. 1 Images of visual effects observed in rat stomachs tested for yeast
fractions: BYPC >3 kDa and BYPP <3 kDa, with reference to the negative
control – saline solution and a positive control – carbonoxolone.
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ance similar to the positive control – carbenoxolone drug used
in the treatment of gastric ulcers,28 with a reduction of 93% of
ULI. This evidence confirms the cytoprotective action against
injuries. Administration of BYPC >3 kDa at 100, 300 and
1000 mg per kg doses did not show a statistical different dose/
effect in terms of ulcerative lesion index (ULI), when compared
to the negative control – saline solution (data not shown).
Furthermore, results revealed a dose–response relationship,
and the effective dose (DE50) obtained by linear regression was
816 mg of BYPP <3 kDa per kg bw (Fig. 2). This optimal dose
was considered in order to study possible mechanisms of
stomach cytoprotection.
Although other sources of peptide extracts and proteins
have been reported as antiulcer agents,9,11,29 this is the first
time that a peptide extract obtained from brewer’s yeast shows
a positive effect against stomach injuries.
3.2 Cytoprotection mechanisms of BY
The gastrointestinal tract is frequently exposed to damaging
stimuli such as anti-inflammatory drugs, alcohol, infections,
stress, etc., which can cause several stomach injuries. In con-
trast to these adverse stimuli, gastrointestinal mucosa presents
endogenous gastroprotective mediators, including prostaglan-
dins, sulfhydryl compounds and nitric oxide. These mecha-
nisms were explored in this research, in order to find the
possible pathway involved in the anti-ulcerative effect, since
the administration of yeast extract reduced significantly the
number of lesions caused by ethanol when administered in
rats. In this way, if BYPP <3 kDa exerted their activity by inter-
fering at least with one of the mechanisms studied, the con-
comitant administration of BYPP <3 kDa with a blocking agent
would prevent the manifestation of gastroprotective effects.
Nitric oxide (NO), represents an important element in the
gastric cytoprotection; it is an endogenous substance that
increases the blood flow of the mucosa and inhibits the
release of oxygenated metabolites.30 To clarify the NO role in
the effect of BYPP <3 kDa, L-NAME was used to inhibit NO pro-
duction, by blocking of NO synthase.31 The administration of
the extract combined with L-NAME did not affect its anti-
ulcerogenic activity, inhibiting the number of ulcerative
lesions 71.2% (Fig. 3), thus discarding the hypothesis that the
extracts may be interfering with the synthesis of NO.
The same approach was used to assess the putative involve-
ment of sulfhydryl compounds. These compounds are present
in gastric mucosa preventing an increase in vascular per-
meability and free radical toxicity.32 The previous adminis-
tration of NEM, inactivates SH compounds. In Fig. 4, it was
observed that the BYPP <3 kDa maintains the antiulcer activity,
showing an 87.7% reduction of gastric injury, demonstrating
Fig. 2 Effect of oral administration of BYPP <3 kDa (100, 300 and
1000 mg kg−1) in ethanol-induced ulcer model in rats. Duncan test
*p < 0.001.
Fig. 3 Effect of oral administration of BYPP <3 kDa in ethanol-induced
ulcer model in rats previously treated with L-NAME (5 mg kg−1). Duncan
test *p < 0.01 **p < 0.001.
Fig. 4 Effect of oral administration of BYPP <3 kDa in ethanol-induced
ulcer model in rats previously treated with NEM (10 mg kg−1). Duncan
test *p < 0.001.
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that this mechanism is not involved in this protection
mechanism.
Finally, the prostaglandin pathway stimulates the secretion
of mucous and bicarbonate and increased blood flow of
gastric mucosa.24 Indomethacin was used to inhibit the
cyclooxygenase involved in PG synthesis. Fig. 5 shows an
increase in ULI relative to saline solution observed in rats that
had received indomethacin, which confirms the inhibition of
this pathway. In the case of BYPP <3 kDa treatment with indo-
methacin, it was observed that the extract partially loses the
anti-ulcerative effect, which reduced only 68% of the injuries
compared to the plain extract (without indomethacin) – 87%.
The chemical composition of these extracts suggests that the
protective action may be exerted by a nonspecific mechanism
of cytoprotection, not explored in this study, like changes in
pH and hydrogen ion concentration of gastric secretion, funda-
mental for mucus protection.10 These extracts were obtained
from combined autolysis, hydrolysis and ultrafiltration of yeast
cells, in order to obtain differentiated fractions. The lower MW
fraction – BYPP <3 kDa – possesses compounds such as free
amino acids and peptides with biological activities, i.e., anti-
oxidant,20 which eventually may control inflammatory cytokine
production.33 On the other hand, the antioxidant activity
attributed to these extracts can contribute towards gastric
mucosal protection against free radicals and other aggressive
agents, in the same way as glutathione and prostaglandins.14
In order to prove the role of the extract in specific mechanisms
of control and gastric acid secretion it would be recommended
to use a pyloric ligation model in future.34 In summary, these
results show the BYPP effect on the stimulus of prostaglandin
synthesis conjugated with non-specific mechanisms as promo-
ters of gastric cytoprotection.
The positive results on the brewer’s yeast extract antiulcer
activity are indeed promising for further use in the develop-
ment of functional ingredients for gastric protection.
3.3 Antiproliferative activity
Fig. 6 shows the percentage growth for each cell line in the
presence of different concentrations of doxorubicin positive
control and of BYPC >3 kDa and BYPP <3 kDa. The horizontal
line at 0% allows to visualize total growth inhibition (TGI),
being the concentration required to inhibit cell growth com-
pletely (full cytostatic effect). Doxorubicin (0.025–25 μg mL−1)
was used as a positive control and it appears that all cell lines
are sensitive to doxorubicin with a TGI at a concentration
range from <0.025 to 0.3 µM. To consider the activity of the
extract, i.e. the antiproliferative capacity, they must show
growth inhibition of higher than 50%, and present a dose-
dependent pattern, demonstrating selectivity for cell types
similar to doxorubicin.25
Regarding the studied yeast extracts, in tested concen-
trations, the extracts did not show a complete cytostatic effect
on the cell lines, except for cell line K-562 (leukemia) showing
inhibition of more than 50% with concentration values of
2.5 µg mL−1 for the extract BYPP <3 kDa and 25 µg mL−1 for
BYPC >3 kDa. The results exhibited a promising antiprolifera-
tive activity against leukemia cells. This effect may be due to
the fact that the yeast has minerals capable of inhibiting the
proliferation of tumor cells35 and other compounds that
present cytostatic effects.36 This is the first time that antiproli-
ferative activity against leukemia cells has been demonstrated
for yeast hydrolysates.
Fig. 5 Effect of oral administration of BYPP <3 kDa in ethanol-induced
ulcer model in rats pretreated with indomethacin (5 mg kg−1). Duncan
test *p < 0.01 **p < 0.001.
Fig. 6 Antiproliferative activity upon nine line cells of cancer of doxorubicin (A) and yeast extracts: BYPC >3 kDa (B) BYPP <3 kDa (C).
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4. Conclusions
Based on the results presented in this study, we conclude that
peptide extracts (in particular BYPP <3 kDa) obtained from the
hydrolysis of proteins from spent brewer’s yeast show a protec-
tive effect on gastric mucosa of rats against ulcerative lesions
caused by ethanol, possibly by a cytoprotective action. The
stimulus of prostaglandin synthesis associated with other
unclarified mechanisms may explain the ability to protect
against gastric lesions. Such evidence is being reported for the
first time for spent brewer’s yeast extracts.
Moreover, the antiproliferative activity assessed for tumor
cells showed that the extracts possess a cytotoxic effect against
leukemia cells that can be potentially useful to the prevention
and treatment of these diseases. Therefore the results pre-
sented in this study, highlight yeast peptide extracts, in par-
ticular the fraction <3 kDa as a promising ingredient for
further utilization in the development of functional foods or to
be used as dietary supplements that can contribute to the pre-
vention of chronic diseases.
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